Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02081027 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
A Early Phase 1 study of Autism Spectrum Disorders, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02081027: Completed Early Phase 1 study of Autism Spectrum Disorders, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT02081027 is a Early Phase 1 study of Autism Spectrum Disorders that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 8 participants, below the 168-participant average among 20 other Autism Spectrum Disorders trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02081027, a Early Phase 1 study of Autism Spectrum Disorders, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine if riluzole shows evidence of efficacy, safety, and tolerability targeting drug-refractory irritability (DRI) in persons with autism spectrum disorders (ASD).
Primary Outcome
A clinician-rated global assessment of symptom change rated on a scale from 1 to 7
Conditions Studied
Interventions
- OTHER placebo
- DRUG Riluzole
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-09-19 |
| Est. Completion | 2015-05 |
| Phase | Early Phase 1 |
What the finished NCT02081027 record still lists
NCT02081027 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 168-participant average among 20 other Autism Spectrum Disorders trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Autism Spectrum Disorders appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02081027 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02081027 about?
NCT02081027 is a clinical study titled "Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders". Determine if riluzole shows evidence of efficacy, safety, and tolerability targeting drug-refractory irritability (DRI) in persons with autism spectrum disorders (ASD).
What is the current status of trial NCT02081027?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2013-09-19. Estimated completion is 2015-05.
What conditions does trial NCT02081027 study?
This clinical trial studies the following conditions: Autism Spectrum Disorders.
What interventions are being tested in trial NCT02081027?
The interventions under investigation include: placebo (OTHER), Riluzole (DRUG).
Who is sponsoring clinical trial NCT02081027?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02081027 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02081027's enrollment target sits among peer trials
8 20th of 20 the lowest of 20 other Autism Spectrum Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Probiotics for Quality of Life in Autism Spectrum Disorders
COMPLETED · Early Phase 1
-
Water Competency Intervention in Autism
RECRUITING · NA
-
Phenotypic and Genetic Factors in Autism Spectrum Disorders
ACTIVE NOT RECRUITING
-
Project AFECT (Autism Family Empowerment Coaching and Training Program)
ACTIVE NOT RECRUITING · NA
-
Telehealth Coaching for Families of Children With Autism
COMPLETED · NA
-
Screening and Linkage to Services for Autism
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI